|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1331 Pennsylvania Ave NW |
Address2 | Suite 1425 North |
| City | WASHINGTON |
State | DC |
Zip Code | 20004-1710 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Washington |
State | DC |
Zip Code | 20004 |
Country | USA |
|
5. Senate ID# 2811-12
|
||||||||
|
6. House ID# 305490000
|
||||||||
| TYPE OF REPORT | 8. Year | 2026 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Laura Katherine Bender |
Date | 4/20/2026 1:16:42 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Issues related to lung disease treatment, prevention and research; public health; tobacco control and air pollution; Issues related to the Affordable Care Act; Issues related to COVID-19 Response; Issues related to infrastructure; Issues related to agency restructuring; Issues relating to FY25 appropriations; Issues relating to FY26 appropriations; S 317 Charitable Act; HR 801 Charitable Act; Consolidated Appropriations Act, 2026; Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026; Breaking the Gridlock Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Natl Institutes of Health (NIH), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ranjana |
Caple |
|
|
|
Elizabeth |
Scott |
|
|
|
Natalia |
Reyes Becerra |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CAW
16. Specific lobbying issues
Issues related to the health impacts of air pollution and climate change; Issues related to air pollution from stationary and mobile sources; Issues related to the Clean Air Act; Issues related to California Clean Air Act waivers; Issues related to permitting and regulatory reforms; Issues related to infrastructure; Issues related to agency restructuring; Issues relating to FY25 appropriations; Issues relating to FY26 appropriations; Issues related to implementation of the Inflation Reduction Act; Issues related to appliance efficiency; issues related to prescribed burning;; S1072 Stop California from Advancing Regulatory Burden Act; H.Con.Res.14 Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; S.Con.Res 7 An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; S 77 Early Participation in Regulations Act; S 81 Guidance Clarity Act; HR 77 Midnight Rules Relief Act; HR 313 Natural Gas Tax Repeal Act; S 143 Natural Gas Tax Repeal Act; HR 471 Fix Our Forests; HJ Res 15/SJ Res 4 Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Energy relating to "Energy Conservation Program: Energy Conservation Standards for Commercial Water Heating Equipment"; HR 903/S 341 Smoke and Heat Ready Communities Act; S 541 Eliminating Lavish Incentives to Electric Vehicles Act; HR 1449 Energy Resilient Communities Act;; S 711 Transportation Freedom Act; HR 1651 To nullify the final rule issued by the Environmental Protection Agency relating to "New Source Performance Standards for Greenhouse Gas Emissions From New, Modified, and Reconstructed Fossil Fuel-Fired Electric Generating Units; Emission Guidelines for Greenhouse Gas Emissions From Existing Fossil Fuel-Fired Electric Generating Units; and Repeal of the Affordable Clean Energy Rule"; HR 1415/S 623 No Industrial Restrictions In Secret (No IRIS) Act; HR 2140 DERA Act 2025; S 1072 A bill to amend the Clean Air Act to eliminate a waiver under that Act, to eliminate an authorization for States to use new motor vehicle emission and new motor vehicle engine emissions standards identical to standards adopted in California, and for other purposes; HR 2165 Choice in Automobile Retail Sales (CARS) Act; HR 346 Preserving Choice in Vehicle Purchases Act; S 990 Freedom to Haul Act; HR 2288 To nullify the final rule of the Environmental Protection Agency titled "Reconsideration of the National Ambient Air Quality Standards for Particulate Matter"; ; HJ Res 30/SJ Res 14 Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Phasedown of Hydrofluorocarbons: Management of Certain Hydrofluorocarbons and Substitutes Under the American Innovation and Manufacturing Act of 2020"; S 1166 Excess Urban Heat Mitigation Act; HR 4214 To require the Administrator of the Environmental Protection Agency to publish, concurrently with any final rule establishing or revising a national ambient air quality standard, regulations and guidance for implementing the standard, including information relating to submission and consideration of a preconstruction permit application under the new or revised standard, and for other purposes; HR 3889/S 2015 National Prescribed Fire Act; H.Res. 585 Recognizing the threat of extreme weather to childrens health and wellbeing, and expressing the sense of Congress that solutions must be rapidly and equitably developed and deployed to address the unique vulnerabilities and needs of children; HR 4443/S 2298 Asuncion Valdivia Heat Illness, Injury, and Fatality Prevention Act; S 2340/HR 4515 Climate Change Health Protection and Promotion Act of 2025; HR 4744/S 2445 Community Mental Wellness and Resilience Act; HR 161 New Source Review Permitting Improvement Act; HR HR 6387 Fire Improvement and Reforming Exceptional Events Act; HR 6409 Foreign Emissions and Nonattainment Clarification for Economic Stability Act; HR 6398 Reducing and Eliminating Duplicative Environmental Regulations Act; HR 6373 Air Permitting Improvements to Protect National Security Act; H.R. 4214 Clean Air and Building Infrastructure Improvement Act; S 2431 Department of the Interior, Environment, and Related Agencies Appropriations Act, 2026; HR 4754 Department of the Interior, Environment, and Related Agencies Appropriations Act, 2026; HR 4553 Energy and Water Development and Related Agencies Appropriations Act, 2026; HR 4776 SPEED Act; S 3529 Public Health Air Quality Act; S 3007, Diesel Truck Liberation Act; S 237 Honoring Our Fallen Heroes Act; Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026; Protection of Lawful Commerce in Stone Slab Products Act; Home Appliance Protection and Affordability Act; Homeowner Energy Freedom Act; Energy Bills Relief Act; Promoting Reduction of Emissions through Landscaping Act; Discussion Draft of Legislation to Modernize the Toxic Substances Control Act; SHOWER Act; Affordable HOMES Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA), Centers For Disease Control & Prevention (CDC), Energy - Dept of, Office of Management & Budget (OMB), Transportation - Dept of (DOT), Natl Highway Traffic Safety Administration (NHTSA), Health & Human Services - Dept of (HHS), Interior - Dept of (DOI), Internal Revenue Service (IRS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Elizabeth |
Scott |
|
|
|
Natalia |
Reyes Becerra |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues related to lung disease treatment, prevention and research; Issues related to public health; Issues related asthma, COPD, influenza, lung cancer, pneumonia, pulmonary fibrosis, tuberculosis and other lung diseases; Issues related to tobacco cessation; Issues related to the Affordable Care Act; Issues related to agency restructuring; Issues related to the Childrens Health Insurance Program; Issues related to Medicaid; Issues related to ERISA; Issues related to COVID-19 Response; Issues related to vaccines; Issues related to infrastructure; Issues related to supplemental oxygen; Issues related to the implementation of the No Surprises Act; Issues related to Medicare sequestration; Issues related to Cancer Moonshot; Issues related to short-term limited duration plans; Issues related to Healthy Future Taskforce; Issues related to regulatory reform; Issues relating to FY25 appropriations; Issues relating to FY26 appropriations; S 1406 the Supplemental Oxygen Access Reform Act; HR 2902 the Supplemental Oxygen Access Reform Act; H.R. 783 Sustainable Cardiopulmonary Rehabilitation Services in the Home Act; S. 248 Sustainable Cardiopulmonary Rehabilitation Services in the Home Act; S 717Increasing Access to Quality Cardiac Rehabilitation Care Act of 2025; S 77 Early Participation in Regulations Act; S 81 Guidance Clarity Act; HR 77 Midnight Rules Relief Act; H.R. 3701 Family Vaccine Protection Act; H.R. 3521 Clinical Trial Modernization Act; HR 4417 Mobile Cancer Screening Act
HR 3701 Family Vaccine Protection Act; HR 5304Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; S 2587 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; HR 5278/S 2756 Affordable Inhalers and Nebulizers Act of 2025; HR 6703 Lower Health Care Premiums for All Americans Act; S 2466 Senior Savings Protection Act; HR Senior Savings Protection Act; HR 6052 Elijah E. Cummings Family Asthma Act; HR 6319 Benay Taub Lung Cancer Research Act; HR 45448 Protecting Free Vaccines Act; Consolidated Appropriations Act, 2026; Breaking the Gridlock Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ranjana |
Caple |
|
|
|
Natalia |
Reyes Becerra |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Issues relating to FY25 appropriations; Issues relating to the Presidents FY26 budget; Issues related to asthma, COPD, influenza, lung cancer, pneumonia, pulmonary fibrosis, tuberculosis and other lung diseases; Issues related to NIH reorganization; Issues related to agency restructuring; Issues related to lung disease treatment, prevention and research; Issues related to COVID-19; Issues related to telehealth; Issues related to infrastructure; Issues related to supplemental oxygen; Issues related to health equity; Issues related to Cancer Moonshot; Issues related to CDC public health workforce and data modernization; Issues related to regulatory reform; Issues related to Medicaid; H.R. 1509/S. 752, the Accelerating Kids Access to Care Act; H.Con.Res.14 Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; S.Con.Res 7 An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; S 1406 the Supplemental Oxygen Access Reform Act; HR 2902 the Supplemental Oxygen Access Reform Act; H.R. 783 Sustainable Cardiopulmonary Rehabilitation Services in the Home Act; S. 248 Sustainable Cardiopulmonary Rehabilitation Services in the Home Act; S 717 Increasing Access to Quality Cardiac Rehabilitation Care Act of 2025; S 77 Early Participation in Regulations Act; S 81 Guidance Clarity Act; HR 77 Midnight Rules Relief Act; H.R. 3521 Clinical Trial Modernization Act; HR 4417 Mobile Cancer Screening Act; HR 5304 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; S 2587 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; HR 5278/S 2756 Affordable Inhalers and Nebulizers Act of 2025; HR 45448 Protecting Free Vaccines Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ranjana |
Caple |
|
|
|
Natalia |
Reyes Becerra |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to lung disease treatment, prevention and research; Issues related to public health; Issues related to tobacco cessation; Issues related to health inequities; Issues related to Medicaid waivers; Issues related to agency restructuring; Issues related to the Affordable Care Act; Issues related to supplemental oxygen; Issues related to access to healthcare; Issues related to COVID-19 Response; Issues related to Medicaid; Issues related to infrastructure; Issues related to health equity; Issues related to the implementation of the No Surprises Act; Issues related to Medicaid; Issues relating to the Presidents FY25 budget; Issues related to regulatory reform; Issues relating to FY25 appropriations; Issues relating to FY26 appropriations; H.Con.Res.14 Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; S.Con.Res 7 An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; S 1406 the Supplemental Oxygen Access Reform Act; HR 2902 the Supplemental Oxygen Access Reform Act; H.R. 783 Sustainable Cardiopulmonary Rehabilitation Services in the Home Act; S. 248 Sustainable Cardiopulmonary Rehabilitation Services in the Home Act; S 77 Early Participation in Regulations Act; S 81 Guidance Clarity Act; HR 77 Midnight Rules Relief Act; S 717 Increasing Access to Quality Cardiac Rehabilitation Care Act of 2025; HR 6178 Increasing Access to Lung Cancer Screening Act; HR 6321 Lung Cancer Medicare Access to Precise Testing Act; HR 6320 Improving Medicaid Precision and Cancer Test Act of 2025
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ranjana |
Caple |
|
|
|
Natalia |
Reyes Becerra |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
Issues related to tobacco use, lung cancer, lung disease treatment, prevention and research; and public health; Issues relating to the Presidents FY25 budget; Issues relating to FY25 appropriations; Issues relating to FY26 appropriations; Issues related to the Congressional Directed Medical Research Program; HR 4016 Department of Defense Appropriations Act, 2026; S 2572 Department of Defense Appropriations Act, 2026
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ranjana |
Caple |
|
|
|
Natalia |
Reyes Becerra |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
Issues related to lung disease treatment, prevention and research; Issues related to tobacco cessation; Issues related to agency restructuring; Issues related to smokefree air; Issues related to the Tobacco Control Act; Issues related to tobacco smuggling; Issues related to the Affordable Care Act; Issues related to menthol cigarettes; Issues related to tobacco prevention; Issues related to youth cessation research; Issues related to nicotine; Issues related to health equity; Issues related to COVID-19 Response; Issues related to tobacco litter; Issues related to synthetic nicotine; Issues related to regulatory reform; Issues relating to FY25 appropriations; Issues relating to FY26 appropriations; S 77 Early Participation in Regulations Act; S 81 Guidance Clarity Act; HR 77 Midnight Rules Relief Act; S. 2171 A bill to amend title 38, united States Code, to prohibit smoking on the premises of any facility of the Veterans Health Administration, and for other purposes; H.R. 4121 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; S 2256 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; HR 6844 The Tobacco Tracking, Reporting, and Accountability for Compliance in Enforcement Act; HR 6845 Strengthening Task Force Operations to Prevent Illicit Vaping Act; S 3569 Strengthening Task Force Operations to Prevent Illicit Vaping Act; Resources to Prevent Youth Vaping Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ranjana |
Caple |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues related to taxes on tobacco products; Issues related to the Affordable Care Act; Issues related to COVID-19; Issues related to infrastructure; Issues relating to the Presidents FY25 budget; Issues relating to FY26 appropriations; S 317 Charitable Act; HR 801 Charitable Act; H.Con.Res.14 Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; S.Con.Res 7 An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Elizabeth |
Scott |
|
|
|
Ranjana |
Caple |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Issues related to lung disease treatment, prevention and research; Issues related to burn pits; Issues related to tobacco cessation; Issues related to smokefree air; Issues related to COVID-19 Response; Issues relating to FY25 appropriations; Issues relating to FY26 appropriations; S. 2171 A bill to amend title 38, united States Code, to prohibit smoking on the premises of any facility of the Veterans Health Administration, and for other purposes
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ranjana |
Caple |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |